WHO contradicts US drug company stance on Remdesivir, says it has little effect on COVID-19
The World Health Organisation (WHO) has contradicted the position of a US company on the potentiality of remdesivir, an antiviral drug considered as one of the treatments for COVID-19.
The organisation, WHO declared that Remdesivir has little or no effect on mortality or reduction in the hospital stays for patients.
This declaration by the health organisation was made in relation to the data from WHO’s solidarity trial.
The trial, conducted among 11,000 patients in 30 countries, involved four potential treatments — remdesivir, hydroxychloroquine, lopinavir/ritonavir, HIV drug combination and interferon.
In a statement released on Thursday, WHO said the results of the trial which are yet to be reviewed suggest that remdesivir and three other existing medications for the treatment of COVID-19 have no substantial effect on mortality or on the length of time spent in the hospital.
Remdesivir was the first drug to recieve the approval of the European Commission in the treatment of severe cases of COVID-19 in July despite questions about its effectiveness.
The EU had signed a contract with Gilead Sciences, US biopharmaceutical company, for 30,000 doses of the drug on behalf of EU member states.
In April, Gilead had announced that the drug was found to be effective on COVID-19 patients during its clinical trial which began in February, adding that it administered the drug on 397 severely ill patients and more than half of them were discharged within two weeks.
A study conducted by Gilead which concludrd that patients receiving remdesivir recovered five days faster and in patients with severe disease, seven days faster than those given a placebo but WHO’s result contradicts the study.
The trial involved 1,060 hospitalised patients worldwide.
The pharmaceutical company also said the drug reduces the likelihood of patients progressing to severe stages of the disease and that it showed significant reduction in mortality.
However, WHO noted that newer antiviral drugs, immunomodulators and anti-SARS COV-2 monoclonal antibodies are now being considered for evaluation for new COVID-19 treatment options.